Literature DB >> 27884624

Serum IL-21 levels are elevated in atopic dermatitis patients with acute skin lesions.

Hiromi Mizutani1, Risa Tamagawa-Mineoka2, Naomi Nakamura1, Koji Masuda1, Norito Katoh1.   

Abstract

BACKGROUND: Interleukin (IL)-21 is a member of the type I cytokine family and plays a role in the pathogenesis of T helper type 2 allergic diseases. It has been reported that IL-21 expression is upregulated in acute skin lesions in atopic dermatitis (AD) patients; however, little is known about the serum IL-21 levels of AD patients. The aim of this study was to quantify the serum IL-21 levels of AD patients and to evaluate the relationships between the serum IL-21 level and disease severity, laboratory markers, and eruption type in AD patients.
METHODS: We measured the serum IL-21 levels of adult AD patients and healthy control subjects using an enzyme-linked immunosorbent assay.
RESULTS: The adult AD patients exhibited significantly higher serum IL-21 levels than the healthy control subjects. A comparison of the patients' serum IL-21 levels based on the clinical severity of their AD revealed that the patients with severe AD demonstrated significantly higher serum IL-21 levels than those with mild AD and the healthy control subjects. The serum IL-21 levels were significantly correlated with the skin severity score, and especially with the degree of acute lesions such as erythema and edema/papules. The serum IL-21 level was not associated with laboratory markers, such as the serum IgE level, the serum thymus and activation-related chemokine level, blood eosinophilia, and the serum lactate dehydrogenase level.
CONCLUSIONS: These results suggest that IL-21 might be involved in the pathogenesis of AD, especially the development of acute skin lesions.
Copyright © 2016 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Atopy; Cytokine; Interleukin 21; T helper 2

Mesh:

Substances:

Year:  2016        PMID: 27884624     DOI: 10.1016/j.alit.2016.10.010

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  5 in total

Review 1.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

2.  Association of Genetic Polymorphisms with Atopic Dermatitis, Clinical Severity and Total IgE: A Replication and Extended Study.

Authors:  Jeong Hyun Kim; So Yeon Lee; Mi Jin Kang; Jisun Yoon; Sungsu Jung; Hyun Ju Cho; Hyo Bin Kim; Soo Jong Hong
Journal:  Allergy Asthma Immunol Res       Date:  2018-07       Impact factor: 5.764

3.  Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes.

Authors:  Guanlan Xu; Tiffany D Grimes; Truman B Grayson; Junqin Chen; Lance A Thielen; Hubert M Tse; Peng Li; Matt Kanke; Tai-Tu Lin; Athena A Schepmoes; Adam C Swensen; Vladislav A Petyuk; Fernando Ovalle; Praveen Sethupathy; Wei-Jun Qian; Anath Shalev
Journal:  Nat Commun       Date:  2022-03-03       Impact factor: 14.919

4.  Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.

Authors:  Jonathan T Sims; Ching-Yun Chang; Richard E Higgs; Sarah M Engle; Yushi Liu; Sean E Sissons; George H Rodgers; Eric L Simpson; Jonathan I Silverberg; Seth B Forman; Jonathan M Janes; Stephanie C Colvin; Emma Guttman-Yassky
Journal:  Exp Dermatol       Date:  2021-06-09       Impact factor: 4.511

5.  Identification of Keratinocyte Mitogens: Implications for Hyperproliferation in Psoriasis and Atopic Dermatitis.

Authors:  Hanna Niehues; Gijs Rikken; Ivonne M J J van Vlijmen-Willems; Diana Rodijk-Olthuis; Piet E J van Erp; Patrick L J M Zeeuwen; Joost Schalkwijk; Ellen H van den Bogaard
Journal:  JID Innov       Date:  2021-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.